Lea Knight compensation by year
INTEGRA LIFESCIENCES Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $295,385 | $616,662 | $638,646 |
| Bonus | $350,000 | $281,942 | $154,897 |
| Stock awards | $1,000,000 | $1,584,589 | $1,498,719 |
| Option awards | $0 | $428,189 | $499,574 |
| Non-equity incentive | $0 | $220,284 | $77,158 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $27,762 | $13,800 | $14,000 |
| Total | $1,673,147 | $3,145,466 | $2,882,994 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INTEGRA LIFESCIENCES HOLDINGS CORP DEF 14A filed April 6, 2026, accession 0000917520-26-000015, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 49,381 | $613,312 | — |
| PSU | 43,793 | $543,909 | — |
| Option | 44,171 | — | $23.95 |
| Option | 20,481 | — | $36.22 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INTEGRA LIFESCIENCES HOLDINGS CORP's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments INTEGRA LIFESCIENCES discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Disability | $0 | $613,312 | $0 | $613,312 |
| Change in control and involuntary termination | $3,029,611 | $1,328,207 | $0 | $4,357,818 |
| Change in control and resignation for good reason | $3,029,611 | $1,328,207 | $0 | $4,357,818 |
| Involuntary termination without cause | $0 | $0 | $0 | $0 |
| Death | $0 | $613,312 | $0 | $613,312 |
Per the Potential Payments Upon Termination or Change in Control table in INTEGRA LIFESCIENCES HOLDINGS CORP's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
INTEGRA LIFESCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mojdeh Poul | President and Chief Executive Officer and Director | $9,375,551 |
| Lea Knight · this page | Executive Vice President and Chief Financial Officer | $2,882,994 |
| Michael McBreen | Executive Vice President, President, Codman Specialty Surgical | $2,713,278 |
| Robert Davis, Jr. | Executive Vice President, President, Tissue Technologies | $1,912,633 |
| Harvinder Singh | Executive Vice President, President, International | $1,625,444 |
| Jan De Witte | Former President and Chief Executive Officer and Director | $282,679 |
The full INTEGRA LIFESCIENCES compensation record
free company briefThis page is one person within INTEGRA LIFESCIENCES's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order INTEGRA LIFESCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INTEGRA LIFESCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat